Abstract
Antimuscarinics are currently the mainstay of pharmacotherapy of the overactive bladder (OAB) syndrome. Several meta-analyses have confirmed their efficacy in comparison with placebo, although the clinical significance of differences in parameters recorded in clinical trials has been questioned. Trials examining the effect of antimuscarinics on outcomes which matter to the patients, such as subjective cure/improvement rates, quality of life parameters and cost-effectiveness are relatively limited. Also, comparative studies between the various available drugs have been designed to support the registration requirements and rarely provide information critical for a physician who needs to assess the best first-line choice for the specific patient, or even a second-line management. Data which might be useful for clinicians who would embark on tailoring the management of OAB for the individual patient could be found in systematic reviews/meta-analyses, cost-effectiveness studies and studies investigating the patients’ adherence to treatment and persistence with pharmacotherapy for OAB. In addition, patient co-morbidities and concurrent treatments should be taken into consideration in conjunction with the safety profile of each antimuscarinic. Available evidence suggests that the use of ER formulations of antimuscarinics is favoured over the IR formulations when concerning best balance between efficacy and adverse events, cost-effectiveness, adherence and persistence with treatment.
Keywords: Antimuscarinics, anticholinergics, systematic review, meta-analysis.
Current Drug Targets
Title:Antimuscarinics in the Treatment of OAB: Is there a First-Line and a Second-Line Choice?
Volume: 16 Issue: 11
Author(s): Apostolos Apostolidis
Affiliation:
Keywords: Antimuscarinics, anticholinergics, systematic review, meta-analysis.
Abstract: Antimuscarinics are currently the mainstay of pharmacotherapy of the overactive bladder (OAB) syndrome. Several meta-analyses have confirmed their efficacy in comparison with placebo, although the clinical significance of differences in parameters recorded in clinical trials has been questioned. Trials examining the effect of antimuscarinics on outcomes which matter to the patients, such as subjective cure/improvement rates, quality of life parameters and cost-effectiveness are relatively limited. Also, comparative studies between the various available drugs have been designed to support the registration requirements and rarely provide information critical for a physician who needs to assess the best first-line choice for the specific patient, or even a second-line management. Data which might be useful for clinicians who would embark on tailoring the management of OAB for the individual patient could be found in systematic reviews/meta-analyses, cost-effectiveness studies and studies investigating the patients’ adherence to treatment and persistence with pharmacotherapy for OAB. In addition, patient co-morbidities and concurrent treatments should be taken into consideration in conjunction with the safety profile of each antimuscarinic. Available evidence suggests that the use of ER formulations of antimuscarinics is favoured over the IR formulations when concerning best balance between efficacy and adverse events, cost-effectiveness, adherence and persistence with treatment.
Export Options
About this article
Cite this article as:
Apostolidis Apostolos, Antimuscarinics in the Treatment of OAB: Is there a First-Line and a Second-Line Choice?, Current Drug Targets 2015; 16 (11) . https://dx.doi.org/10.2174/1389450116666150518102021
DOI https://dx.doi.org/10.2174/1389450116666150518102021 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Galanin: A Biologically Active Peptide
Current Drug Targets - CNS & Neurological Disorders Molecular Aspects of Modulation of L-type Calcium Channels by Protein Kinase C
Current Molecular Pharmacology Antioxidants in Health, Disease and Aging
CNS & Neurological Disorders - Drug Targets Activin Receptor-Like Kinases: Structure, Function and Clinical Implications
Endocrine, Metabolic & Immune Disorders - Drug Targets Novel Biomarkers Assessing Renal Function in Heart Failure: Relation to Inflammatory Status and Cardiac Remodelling
Current Medicinal Chemistry The Prospect of Stem Cells as Multi-Faceted Purveyors of Immune Modulation, Repair and Regeneration in Multiple Sclerosis
Current Stem Cell Research & Therapy The Role of Endothelin-1 in Obstructive Sleep Apnea Syndrome and Pulmonary Arterial Hypertension: Pathogenesis and Endothelin-1 Antagonists
Current Medicinal Chemistry Obesity-Associated Hypertension in Childhood: A New Epidemic Problem
Current Hypertension Reviews Pharmacotherapy Before and After Endovascular Repair of Abdominal Aortic Aneurysms
Current Vascular Pharmacology Re-Discovering PDE3 Inhibitors - New Opportunities for a Long Neglected Target
Current Topics in Medicinal Chemistry Systemic Inflammation Induces Endothelial Dysfunction in Peritoneal Dialysis Patients
Vascular Disease Prevention (Discontinued) Isolated-Perfused Heart: The Preparation that has been used as a Research Tool for More than a Century
Drug Design Reviews - Online (Discontinued) Role of Angiotensin-1-Receptor Blockers In Cardiorenal Disease
Current Drug Therapy Antihypertensive Therapy: Role of Aldosterone Antagonists
Current Pharmaceutical Design Cellular and Molecular Mechanisms of Low Cardiac Output Syndrome after Pediatric Cardiac Surgery
Current Vascular Pharmacology Fibromyalgia and Bipolar Disorder: Emerging Epidemiological Associations and Shared Pathophysiology
Current Molecular Medicine Modulation of Staurosporine-Activated Volume-Sensitive Outwardly Rectifying Cl- Channel by PI3K/Akt in Cardiomyocytes
Current Pharmaceutical Design Antimicrobial Agents-Associated with QT Interval Prolongation
Current Drug Safety Cell Life Versus Cell Longevity: The Mysteries Surrounding the NAD+ Precursor Nicotinamide
Current Medicinal Chemistry Transient Receptor Potential (TRP) Channels and Cardiac Fibrosis
Current Topics in Medicinal Chemistry